Xencor, Inc.

NASDAQ:XNCR

Biotechnology

Healthcare
$34.39 -1.03%

-$0.13 today

Market cap
$2.58B
Beta
0.93
P/E (TTM)
-5.5
EPS (TTM)
-$2.29
52W Low $6.92High $18.69

Volume 0.87M

Average 0.80M

XNCR Deferred Revenue (Non-current)

Payments received for goods or services the company will deliver after more than one year.

Xencor, Inc.NASDAQ: XNCR

Deferred Revenue (Non-current) · Q2 FY2026 · quarter ended Jun 2026

Deferred revenue (non-current) remains negative

Q2 FY2026 deferred revenue (non-current) was $77.54M, compared with $0 a year earlier.

Context

  • Deferred revenue (non-current) amounted to 10.7% of total assets at the end of Q2 FY2026, up 10.7 pp from a year earlier.
  • Deferred revenue (non-current) increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$77.54M— QoQ
Last fiscal yearDec 2025
$0— YoY
Year agoJun 2025
$0— since
Deferred Revenue (Non-current) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Deferred Revenue (Non-current) history

USD · from the balance sheet

Latest · FY2025
0 USD
Year-over-year change
—

Deferred Revenue (Non-current) vs competitors

How XNCR compares with its peers on the latest reported figures

  • Peers report in different currencies, so deferred revenue (non-current) is compared through growth and share of total assets rather than absolute size.
  • Deferred revenue (non-current) amounts to 10.7% of total assets for XNCR, versus a peer median of 0.0%.
XNCR Competitors
Deferred Revenue (Non-current) for XNCR and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
GMABGenmab A/SJun 2026$88M USD+31.4%—0.7%
XNCRXencor, Inc.Jun 2026$77.54M USD——10.7%
CGENCompugen Ltd.Mar 2026$22.14M USD-30.3%—15.2%
NRIXNurix Therapeutics, Inc.Aug 2026$10.78M USD-29.0%-34.7%0.9%
IMCRImmunocore Holdings plcMar 2026$4.62M USD-17.6%-2.5%0.4%
CLDXCelldex Therapeutics, Inc.Sep 2026$0 USD——0.0%
NKTRNektar TherapeuticsJun 2026$0 USD——0.0%
IPHAInnate Pharma S.A.Dec 2025€0 EUR-100.0%—0.0%
MGNXMacroGenics, Inc.Mar 2026$0 USD-100.0%-2.3%0.0%
ADAGAdagene Inc.Dec 2025$0 USD——0.0%
IMMPImmutep LimitedDec 2025A$0 AUD——0.0%
Peer median (excluding XNCR) —-29.6%-2.5%0.0%

Competitors are the stored peer set for XNCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents143.48M53.94M53.79M40.88M54.07M
Short-term Investments190.63M569.12M539.94M456.9M493.66M
Net Receivables66.38M29M11.29M60.85M29.3M
Inventory00000
Other Current Assets023.28M18.15M18.98M22.79M
Total Current Assets424.37M675.34M623.16M577.6M599.82M
Property, Plant & Equipment (Net)59.97M93.6M100.12M98.14M90.9M
Goodwill00000
Intangible Assets16.49M18.5M18.66M18.49M8.39M
Long-term Investments331.73M58.21M209.72M256.83M175.89M
Tax Assets5M0000
Other Non-current Assets653K613K1.03M885K498K
Total Non-current Assets413.84M170.92M329.53M374.34M275.67M
Total Assets838.21M846.27M952.69M951.95M875.5M
Account Payables14M10.09M13.91M16.76M10.83M
Short-term Debt006.33M48.45M43.27M
Tax Payables005.78M9.99M3.59M
Deferred Revenue37.29M30.32M31.68M00
Other Current Liabilities00000
Total Current Liabilities70.74M63.84M84.71M87.43M95.91M
Long-term Debt0014.64M115.16M76.48M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00125.18M00
Other Non-current Liabilities0009.99M2.78M
Total Non-current Liabilities33.97M54.93M198.85M190.49M144M
Total Liabilities104.71M118.77M283.56M277.92M239.91M
Common Stock595K601K611K703K718K
Retained Earnings(283.1M)(338.29M)(464.37M)(704.04M)(795.96M)
Accumulated OCI(1.51M)(6.95M)1.29M(663K)1.58M
Other Stockholders Equity00000
Minority Interest00337K(3.59M)0
Total Equity733.5M727.5M669.13M674.03M635.59M
Total Debt33.97M59.63M83.43M231.95M187.75M
Net Debt(109.51M)5.69M29.64M191.08M133.67M

Xencor, Inc.

NASDAQ:XNCR

Intrinsic Alpha fair value

Locked

Current Price

$34.39

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.